Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28357714 | 1.00 | MTNR1A (0.43) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL4347797 | 1.00 | MTNR1A (0.43) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL13705940 | 0.83 | MTNR1A (0.40) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL803827 | 0.78 | MTNR1A (0.41) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12394472 | 0.76 | MTNR1A (0.40) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1516337 | 0.75 | MTNR1B (0.36) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL338470 | 0.75 | MTNR1B (0.39) | MTNR1AMTNR1B | |
| SCHEMBL4688545 | 0.75 | MTNR1B (0.39) | MTNR1AMTNR1B | |
| SCHEMBL339505 | 0.75 | MTNR1B (0.36) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL338471 | 0.75 | MTNR1B (0.39) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | disclosed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | disclosed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | MTNR1A 2639/4885MTNR1B 2677/4885ABCB11 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.